QIAGEN and NVIDIA partner on AI drug discovery

Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases

Drug Safety Symposium 2026 to focus on real-world impact of pharmacovigilance

The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations

Bayer’s stroke drug wins fast-track review in US

The development comes as stroke remains one of the world’s biggest health threats

IGI’s new drug candidate ISB 2301 to target solid tumors

The company intends to file an IND submission by the end of this year and begin clinical studies in 2027

SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer

The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients

Aarti Drugs posts steady FY26 growth & sharp Q4 rebound despite margin pressure

Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug

Baxfendy works in a fundamentally different way from current therapies

Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI

The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy

Altasciences and Certara forge strategic pact to speed early drug development

NIH-funded study uncovers hidden brain circuit behind GLP-1 weight-loss drugs

In the new study, scientists at the University of Virginia used gene-editing techniques to modify GLP-1 receptors in mice to make them more humanlike